|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
TA
|
| ID number |
3834
|
Provisional Schedule
| Committee meeting: 2 |
14 December 2023 |
| Expected publication |
20 March 2024 |
Project Team
Email enquiries
| External Assessment Group |
BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors |
Vertex Pharmaceuticals (elexacaftor, tezacaftor, lumcaftor and ivacaftor) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
CF Voices |
| |
Cystic Fibrosis Trust |
| |
Quest for a CF Cure |
| Professional groups |
Association of Chartered Physiotherapists in Cystic Fibrosis |
| |
British Dietetic Association |
| |
British Paediatric Respiratory Society |
| |
CF Health Hub / CF DigiCare |
| |
Cystic Fibrosis Nursing Association |
| |
Neonatal and Paediatric Pharmacists Group |
| |
Royal College of Paediatrics & Child Health |
| |
Royal College of Physicians |
| |
UK Cystic Fibrosis Medical Association |
| |
UK Cystic Fibrosis Pharmacy Group |
| |
UK Clinical Pharmacy Association |
| |
UK Psychosocial Professionals in Cystic Fibrosis Group |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
National Institute for Health Research |
|
Date
|
Update
|
|
03 November 2023 - 24 November 2023
|
Draft guidance |
|
03 November 2023
|
Access to treatments will continue while the appraisal is ongoing. This will be the case for people starting the treatments as well as those already taking the treatments. Once the appraisal has ended, new patients will only be initiated on treatments that have been recommended in NICE’s final guidance. Existing patients will be unaffected as the flexible commercial mechanism ensures continued access for patients already receiving any of the licensed treatments following the conclusion of a full NICE evaluation. |
|
12 October 2023
|
Committee meeting |
|
29 August 2023
|
Assessment report sent for information |
|
27 January 2023
|
Invitation to participate |
|
27 January 2023
|
In progress. Invitation to participate |
|
18 November 2022 - 16 December 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1 |
For further information on how we select topics for development, please see our page about topic selection